Various theories abound regarding how people make decisions, but at the end of the day, they are all just theories. Until we can climb into people’s heads, we have to rely on psychological theory as a way to explain and understand what’s going on so that we can motivate our target market into taking desired actions.
The result of today’s on-demand culture is the increasing expectations of consumers to always want more, exactly when they want it. And that means the User Interface (UI) is due for a complete revamp to better meet consumers’ desires. The story of Wendy Walker is just a taste of what the near future will look like for UI.
What just about everybody agrees upon is an urgent need for innovation within the realm of clinical research. In the era of smart science and smarter patients, clinical-trial units continue to struggle with a range of recruitment and access issues.
Carlsbad-based fintech startup Bitmo Inc., which previously aimed to turn its app into the mobile alternative of choice to carrying payment cards, has stripped down the product and turned it into a delivery system for social gifting.
“At CureClick believe that clinical trials are the lifeblood of medical progress. Without research, there are no new treatments; no cures. It is critical that we help each other find, understand, and participate in research, when it makes sense.” - Brian Poeschl, COO, CureClick
Alchemy Factory, an incubator focused on helping health and tech startups expedite their product development through capital, infrastructure, mentorship, research and marketing services, has invested $50,000 in Bitmo.
WEGO Health, a network of more than 100,000 patient leaders, today announced it has partnered with CureClick to make patient influencers available through the CureClick clinical trial recruiting platform.
A research study on epilepsy with the Apple Watch and ResearchKit at the core of the work has concluded, and is shedding light on seizure triggers, hopefully paving the way for better identification of precursors of the disruptive and dangerous event.
PMBs and health-plan executives haven't always been vocal about the changes set in motion by the shift to outcomes-based pricing. InVibe, with help from Interactive Forums, polled 13 medical or pharmacy directors. Hear their take on several formulary-related issue.